Core Insights - Myriad Genetics reported $195.9 million in revenue for the quarter ended March 2025, reflecting a year-over-year decline of 3.1% and an EPS of -$0.03 compared to -$0.01 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $199.96 million by 2.03%, while the EPS exceeded the consensus estimate of -$0.05 by 40% [1] Revenue Performance by Product - Prenatal revenue reached $49.30 million, surpassing the estimated $44.69 million, marking a year-over-year increase of 59.6% [4] - Hereditary Cancer revenue was $86.30 million, below the average estimate of $92.46 million, representing a year-over-year decline of 2% [4] - Pharmacogenomics revenue totaled $31 million, slightly below the estimated $32.46 million, with a year-over-year decrease of 20.3% [4] - Tumor Profiling revenue was $29.30 million, compared to the average estimate of $30.66 million, indicating a year-over-year decline of 5.2% [4] Stock Performance - Myriad's shares have returned -4.6% over the past month, contrasting with the Zacks S&P 500 composite's increase of 11.5% [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance against the broader market in the near term [3]

Core Insights - International Flavors (IFF) reported revenue of $2.84 billion for the quarter ended March 2025, reflecting a year-over-year decline of 1.9% [1] - The company's EPS was $1.20, an increase from $1.13 in the same quarter last year, surpassing the consensus estimate of $1.12 by 7.14% [1] Revenue Performance - Health & Biosciences net sales reached $540 million, exceeding the average estimate of $532.05 million, marking a year-over-year increase of 1.7% [4] - Scent segment net sales were $614 million, slightly above the estimated $609.74 million, but down 4.8% compared to the previous year [4] - Pharma Solutions net sales amounted to $266 million, significantly surpassing the estimated $233.97 million, with a year-over-year growth of 17.2% [4] EBITDA Analysis - Adjusted Operating EBITDA for Health & Biosciences was $138 million, below the average estimate of $159.94 million [4] - Pharma Solutions reported an Adjusted Operating EBITDA of $54 million, exceeding the estimated $45.50 million [4] - Scent's Adjusted Operating EBITDA was $144 million, slightly above the average estimate of $140.59 million [4] Stock Performance - IFF shares have returned +11.9% over the past month, outperforming the Zacks S&P 500 composite's +11.5% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3]

Core Insights - Zimmer Biomet reported $1.91 billion in revenue for the quarter ended March 2025, reflecting a year-over-year increase of 1.1% and an EPS of $1.81 compared to $1.94 a year ago, with revenue exceeding the Zacks Consensus Estimate of $1.89 billion by +0.88% and an EPS surprise of +2.84% [1] Revenue Performance - Net Sales for Knees in the United States were $459 million, slightly below the average estimate of $464.68 million, representing a year-over-year change of +0.2% [4] - Net Sales for Hips in the United States reached $264.30 million, surpassing the average estimate of $258.29 million, with a year-over-year increase of +3.7% [4] - International Net Sales for Hips were $231.50 million, slightly above the average estimate of $229.39 million, showing a year-over-year decline of -2% [4] - International Net Sales for Knees were $333.90 million, exceeding the average estimate of $328.76 million, with a year-over-year increase of +1.2% [4] - Total International Net Sales amounted to $795.50 million, surpassing the estimated $783.50 million, reflecting a +0.7% change year-over-year [4] - Total Net Sales in the United States were $1.11 billion, slightly above the estimated $1.10 billion, indicating a +1.3% year-over-year change [4] - Overall Net Sales for Knees were $792.90 million, exceeding the average estimate of $787.14 million, with a year-over-year increase of +0.6% [4] - Net Sales for Other products were $149.90 million, below the average estimate of $152.71 million, representing a year-over-year decline of -4.7% [4] - Net Sales for S.E.T. reached $470.50 million, surpassing the average estimate of $460.26 million, with a year-over-year increase of +4% [4] - Net Sales for Hips totaled $495.80 million, exceeding the average estimate of $488.84 million, reflecting a +0.9% year-over-year change [4] Stock Performance - Zimmer's shares have returned -4.6% over the past month, contrasting with the Zacks S&P 500 composite's +0.4% change, and the stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market [3]

Core Insights - Ardelyx reported $74.11 million in revenue for Q1 2025, a year-over-year increase of 61.1%, but fell short of the Zacks Consensus Estimate by 8.14% [1] - The company posted an EPS of -$0.17, which is a decline from -$0.11 a year ago, resulting in a surprise of -70.00% compared to the consensus estimate of -$0.10 [1] Revenue Breakdown - Product sales netted $67.81 million, below the six-analyst average estimate of $77.61 million, reflecting a year-over-year change of +55.9% [4] - Sales of IBSRELA reached $44.40 million, compared to the average estimate of $53.71 million [4] - Sales of XPHOZAH were $23.41 million, slightly below the estimated $24.55 million [4] - Product supply revenue was $0.25 million, significantly lower than the four-analyst average estimate of $3.70 million, marking a year-over-year decline of 88.1% [4] - Non-cash royalty revenue related to future royalties was $1.03 million, exceeding the average estimate of $0.68 million [4] Stock Performance - Ardelyx shares have returned +12.8% over the past month, contrasting with a -0.7% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Financial Performance - For the quarter ended March 2025, DigitalBridge reported revenue of $45.45 million, down 38.9% year-over-year, and EPS of $0.29, compared to $0.01 in the same quarter last year [1] - The reported revenue was a surprise of -56.61% compared to the Zacks Consensus Estimate of $104.74 million, while the EPS surprise was +262.50% against the consensus estimate of $0.08 [1] Key Metrics - Fee Earning Equity Under Management (FEEUM) stood at $37.3 billion, exceeding the two-analyst average estimate of $36.23 billion [4] - Fee revenue was reported at $90.14 million, surpassing the average estimate of $87.03 million by three analysts, representing a year-over-year increase of +23.6% [4] - Principal investment income (loss) was $5.31 million, below the average estimate of $8.88 million, but showed a year-over-year change of +86.5% [4] - Other income was reported at $5.47 million, compared to the average estimate of $6.63 million, reflecting a year-over-year decline of -22.7% [4] Stock Performance - DigitalBridge shares have returned -8.6% over the past month, while the Zacks S&P 500 composite changed by -0.7% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

For the quarter ended March 2025, Smurfit Westrock (SW) reported revenue of $7.66 billion, up 62% over the same period last year. EPS came in at $0.73, compared to $0.39 in the year-ago quarter.The reported revenue represents a surprise of -2.47% over the Zacks Consensus Estimate of $7.85 billion. With the consensus EPS estimate being $0.65, the EPS surprise was +12.31%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine thei ...

Core Insights - Equinix reported $2.23 billion in revenue for Q1 2025, a year-over-year increase of 4.6%, with an EPS of $9.67 compared to $2.43 a year ago, exceeding both revenue and EPS consensus estimates [1] - The company achieved a revenue surprise of +0.42% and an EPS surprise of +7.92% compared to analyst expectations [1] Financial Performance - Equinix's shares returned +4.3% over the past month, outperforming the Zacks S&P 500 composite, which saw a -0.2% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market [3] Capacity and Revenue Metrics - Cabinet Equivalent Capacity in the Americas was 144,100, slightly below the estimated 145,538 [4] - EMEA's Cabinet Equivalent Capacity was 138,300, compared to an estimate of 139,375 [4] - Asia-Pacific's Cabinet Equivalent Capacity was 89,400, against an estimate of 90,538 [4] - Worldwide Cabinet Equivalent Capacity totaled 371,800, below the average estimate of 375,450 [4] Geographic Revenue Breakdown - Asia-Pacific revenue was $481 million, below the average estimate of $490.44 million [4] - Americas revenue reached $1 billion, exceeding the average estimate of $982.55 million [4] - EMEA revenue was $743 million, slightly below the estimate of $744.53 million [4] - Europe-Recurring-Other revenue was $27 million, above the average estimate of $25.10 million [4] Recurring and Non-Recurring Revenue - Recurring revenues totaled $2.09 billion, matching the five-analyst average estimate [4] - Non-recurring revenues were $138 million, surpassing the average estimate of $128.50 million [4] - Managed infrastructure recurring revenues were $115 million, slightly below the estimate of $117.30 million [4] - Interconnection recurring revenues were $393 million, just below the average estimate of $394.64 million [4]

For the quarter ended March 2025, AvalonBay Communities (AVB) reported revenue of $745.88 million, up 4.6% over the same period last year. EPS came in at $2.83, compared to $1.22 in the year-ago quarter.The reported revenue represents a surprise of -0.19% over the Zacks Consensus Estimate of $747.26 million. With the consensus EPS estimate being $2.80, the EPS surprise was +1.07%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to dete ...

Core Insights - GE HealthCare Technologies (GEHC) reported revenue of $4.78 billion for the quarter ended March 2025, reflecting a year-over-year increase of 2.7% and exceeding the Zacks Consensus Estimate of $4.66 billion by 2.57% [1] - The company's earnings per share (EPS) was $1.01, up from $0.90 in the same quarter last year, resulting in an EPS surprise of 10.99% compared to the consensus estimate of $0.91 [1] Revenue Breakdown - Imaging revenues were reported at $2.14 billion, surpassing the average analyst estimate of $2.03 billion, but showing a decline of 13.2% year-over-year [4] - Other revenues amounted to $13 million, slightly below the estimated $13.30 million, with a year-over-year decrease of 13.3% [4] - PDx revenues reached $632 million, slightly above the estimate of $631.52 million, marking a year-over-year increase of 5.5% [4] - PCS revenues were reported at $753 million, exceeding the average estimate of $749.38 million, with a year-over-year growth of 0.8% [4] Stock Performance - Over the past month, GE HealthCare shares have returned -14.4%, contrasting with a -0.2% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Insights - Snap reported revenue of $1.36 billion for the quarter ended March 2025, reflecting a year-over-year increase of 14.1% and surpassing the Zacks Consensus Estimate of $1.35 billion by 1.15% [1] - The company's EPS for the quarter was $0.04, consistent with the consensus estimate, showing no surprise in earnings [1] Financial Performance Metrics - Daily Active Users (DAU) reached 460 million, slightly above the estimated 458.96 million [4] - Average Revenue Per User (ARPU) globally was $2.96, marginally exceeding the nine-analyst average estimate of $2.95 [4] - DAU in North America was 99 million, slightly below the estimate of 100.09 million [4] - DAU in Europe was 99 million, in line with the estimate of 99.09 million [4] - DAU in the Rest of World segment was 262 million, surpassing the estimate of 259.68 million [4] - ARPU in Europe was $2.26, below the estimated $2.29 [4] - ARPU in the Rest of World was $1.17, lower than the $1.23 estimate [4] - ARPU in North America was $8.41, exceeding the estimate of $7.99 [4] - The total number of full-time employees was 5.06 billion, above the estimate of 4.99 billion [4] Geographic Revenue Breakdown - Revenue from Europe was $224.02 million, below the estimate of $231.11 million, but represented a year-over-year increase of 14.4% [4] - Revenue from the Rest of World was $307.51 million, below the estimate of $321.62 million, with a year-over-year increase of 20.2% [4] - Revenue from North America was $831.69 million, exceeding the estimate of $793.09 million, with a year-over-year increase of 11.9% [4]